The effects of lifestyle modification on a new oxidized low-density lipoprotein marker, serum amyloid A-LDL, in subjects with primary lipid disorder

Clinica Chimica Acta

Volumn 409, Issue 1-2, 2009, Pages 67-69

  Kotani, Kazuhiko ^a   Koibuchi, Harumi ^a   Yamada, Toshiyuki ^a   Taniguchi, Nobuyuki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Body mass index; Endothelium; High density lipoprotein; Oxidation; Triglyceride

Indexed keywords

BIOCHEMICAL MARKER; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; SERUM AMYLOID A; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIET; DYSLIPIDEMIA; EXERCISE; FEMALE; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTIPLE REGRESSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LIFE STYLE; LIPID METABOLISM DISORDERS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SERUM AMYLOID A PROTEIN;

EID: 70349826209     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.08.019     Document Type: Article

References (33)

1. Japan Atherosclerosis Society. Japan Atherosclerosis Society guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases (in Japanese). 1 (2002), Atherosclerosis Society, Tokyo, Japan 24-26
2. Teramoto T., Sasaki J., Ueshima H., et al. Goals of dyslipidemia management. J Atheroscler Thromb 14 5 (2007) 209-212
3. Holvoet P. Oxidized LDL and coronary heart disease. Acta Cardiol 59 5 (2004) 479-484
4. Lind L., Andersson J., Rönn M., et al. Brachial artery intima-media thickness and echogenicity in relation to lipids and markers of oxidative stress in elderly subjects:- the prospective investigation of the vasculature in Uppsala Seniors (PIVUS) Study. Lipids 43 2 (2008) 133-141
5. Chen H.W., Kuo C.L., Huang C.S., Kuo S.J., and Liu C.S. Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population. Cardiology 110 4 (2008) 252-259
6. Itabe H., and Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 14 1 (2007) 1-11
7. Ogasawara K., Mashiba S., Wada Y., et al. A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis 174 2 (2004) 349-356
8. Malle E., and De Beer F.C. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26 6 (1996) 427-435
9. Urieli-Shoval S., Linke R.P., and Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7 1 (2000) 64-69
10. Marhaug G., Sletten K., and Husby G. Characterization of amyloid related protein SAA complexed with serum lipoprotein (apoSAA). Clin Exp Immunol 50 2 (1982) 382-389
11. Kotani K., Satoh N., Kato Y., et al. A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome. Atherosclerosis 204 2 (2009) 526-531
12. de la Sierra A., and Ruilope L.M. Management of cardiovascular risk factors in patients with metabolic syndrome. Cardiovasc Hematol Agents Med Chem 5 3 (2007) 209-214
13. Therond P. Catabolism of lipoproteins and metabolic syndrome. Curr Opin Clin Nutr Metab Care 12 4 (2009) 366-371
14. Yamamoto R., Kawamura T., Wakai K., et al. Favorable life-style modification and attenuation of cardiovascular risk factors. Jpn Circ J 63 3 (1999) 184-188
15. Roberts C.K., Ng C., Hama S., Eliseo A.J., and Barnard R.J. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 101 6 (2006) 1727-1732
16. Kotani K., Mu H., Kamezaki S., Kato T., and Kurozawa Y. Clinical importance of the evaluation of blood non-HDL cholesterol levels in a hypercholesterolemia education class. Intern Med 45 10 (2006) 697-698
17. Grundy S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5 4 (2006) 295-309
18. Knopp R.H., Paramsothy P., Atkinson B., and Dowdy A. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am J Cardiol 101 8A (2008) B48-B57
19. Rau O., Zettl H., Popescu L., Steinhilber D., and Schubert-Zsilavecz M. The treatment of dyslipidemia-what's left in the pipeline?. Chem Med Chem 3 2 (2008) 206-221
20. Panagiotakos D.B., Pitsavos C., Chrysohoou C., Skoumas J., and Stefanadis C. Status and management of blood lipids in Greek adults and their relation to socio-demographic, lifestyle and dietary factors: the ATTICA Study. Blood lipids distribution in Greece. Atherosclerosis 173 2 (2004) 353-361
21. Rector R.S., Warner S.O., Liu Y., et al. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab 293 2 (2007) E500-E506
22. Diwadkar V.A., Anderson J.W., Bridges S.R., Gowri M.S., and Oelgten P.R. Postprandial low-density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 222 2 (1999) 178-184
23. Batt K.V., Avella M., Moore E.H., Jackson B., Suckling K.E., and Botham K.M. Differential effects of low-density lipoprotein and chylomicron remnants on lipid accumulation in human macrophages. Exp Biol Med 229 6 (2004) 528-537
24. Koonen D.P., Jacobs R.L., Febbraio M., et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 56 12 (2007) 2863-2871
25. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 6 (1995) 2882-2891
26. Navab M., Berliner J.A., Subbanagounder G., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 4 (2001) 481-488
27. Dart A.M., and Chin-Dusting J.P. Lipids and the endothelium. Cardiovasc Res 43 2 (1999) 308-322
28. Calabresi L., Gomaraschi M., and Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 23 10 (2003) 1724-1731
29. Norata G.D., and Catapano A.L. Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc Health Risk Manag 1 2 (2005) 119-129
30. Giannattasio C., Zoppo A., Gentile G., et al. Acute effect of high-fat meal on endothelial function in moderately dyslipidemic subjects. Arterioscler Thromb Vasc Biol 25 2 (2005) 406-410
31. Norata G.D., Grigore L., Raselli S., et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: Molecular mechanisms and gene expression studies. Atherosclerosis 193 2 (2007) 321-327
32. Navab M., Yu R., Gharavi N., et al. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep 9 3 (2007) 244-248
33. Barter P.J., Puranik R., and Rye K.A. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 9 6 (2007) 493-498